Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DW43DG
|
|||
| Drug Name |
Bimagrumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 2 | [1] | |
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Activin receptor type II (ACVR2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03005288) Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes. U.S. National Institutes of Health. | |||
| REF 2 | Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol (Oxf). 2018 Jun;88(6):908-919. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.